The Effects of a Botanical Moisturizer and an Unscented Soap on Eczema and Itch

January 30, 2025 updated by: Codex Labs Corporation

Clinical and Instrumental Efficacy Evaluation on Eczema of One Cosmetic Product

The purpose of this study is to examine the effects of a botanical moisturizer and an unscented soap on eczema severity, itch, mood, and various skin measures (such as skin hydration) in those with mild to moderate eczema.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Gdansk, Poland
        • Eurofins Dermscan Poland

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sex: female and male;
  • Age : 18 years old and above;
  • Phototype: I to IV;
  • Type: Caucasian;
  • Subjects with active eczema condition the body (showing flakiness, irritation, itch and intense dryness);
  • Subjects with a SCORAD of 25 - 50;
  • Subjects with dry skin on the study areas;
  • Subject barely wearing makeup;
  • Subjects must not take antibiotics and / or apply any antifungal treatments (body/scalp) for 1 month before study start and during the entire study duration;
  • No change in hygiene, cosmetics, and make-up habits - except for the product(s) under study - during the entire study duration;
  • Subjects agreeing not to change lifestyle habits during the study duration.
  • Healthy subject;
  • Subject having given her free informed, written consent;
  • Subject willing to adhere to the protocol and study procedures;
  • Subject with Polish citizenship.

Exclusion Criteria:

  • For women with childbearing potential: pregnant or nursing woman or woman planning to get pregnant during the study;
  • Cutaneous pathology on the study zone (other than eczema);
  • Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the study product (the subjects are allowed to use their topical corticosteroids during the study if needed; the information about the treatment and the number of applications must be noted in the daily log);
  • Subject having undergone a surgery under general anesthesia within the previous month;
  • Excessive exposure to sunlight or UV-rays within the previous month;
  • Subject enrolled in another clinical trial during the study period (concerns the studied zones).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Participant
The participant is provided with and instructed to use a botanical moisturizer on the body for the duration of the study. The participant is also provided with and instructed to use an unscented soap, in replacement of the participant's usual cleansing product for the duration of the study.

The intervention includes the use of 2 products:

  1. A botanical moisturizer
  2. An unscented bar of soap

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective and Subjective Scoring of Eczema Severity
Time Frame: 8 weeks

Change in eczema severity was assessed using SCORAD (SCOring of Atopic Dermatitis).

A. First, the spread of eczema on different body areas is assessed by the investigator and calculated as a percent, where the maximum is 100%.

B. Second, the intensity of skin redness, swelling, oozing, scratch marks, skin thickening and dryness is scored by the investigator from 0 to 3, where 0 is none, 1 is mild, 2 is moderate, and 3 is severe.

C. Finally, for the subjective score, participants are asked to report the intensity of symptoms (itch and sleeplessness) from 0 to 10, where 0 is no itch or no sleeplessness, and 10 is the worst imaginable itch or insomnia sleeplessness.

The total score of the objective SCORAD is obtained with the following formula:

SCORAD = A/5 + 7 B/2 + C

8 weeks
Localized Eczema Severity
Time Frame: 4 weeks

Change in localized eczema severity is assessed with the Eczema Area and Severity Index (EASI).

Skin redness, elevation, scratching, and thickening are assessed by the investigator on a scale of 0 to 3, where 0 is none, 1 is mild, 2 is moderate, 3 is severe. The localized EASI is the sum of these scores.

4 weeks
Localized Eczema Severity
Time Frame: 8 weeks

Change in localized eczema severity is assessed with the Eczema Area and Severity Index (EASI).

Skin redness, elevation, scratching, and thickening are assessed by the investigator on a scale of 0 to 3, where 0 is none, 1 is mild, 2 is moderate, 3 is severe. The localized EASI is the sum of these scores.

8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skin Hydration
Time Frame: 4 weeks
Change in skin hydration is assessed with a Corneometer.
4 weeks
Skin Hydration
Time Frame: 8 weeks
Change in skin hydration is assessed with a Corneometer.
8 weeks
Transepidermal Water Loss
Time Frame: 4 weeks
Change in transepidermal water loss is assessed with a Tewameter TM 300
4 weeks
Transepidermal Water Loss
Time Frame: 8 weeks
Change in transepidermal water loss is assessed with a Tewameter TM 300
8 weeks
Desquamation Index
Time Frame: 4 weeks
Change in desquamation is assessed with D-Squam®.
4 weeks
Desquamation Index
Time Frame: 8 weeks
Change in desquamation is assessed with D-Squam®.
8 weeks
Positive and Negative Affect
Time Frame: 4 weeks

Change in mood is assessed with the PANAS-SF (Positive and Negative Affect Schedule- Short Form).

Participants are asked to evaluate the degree to which they experienced components of positive and negative affect : Interested, Distressed, Excited, Upset, Strong, Guilty, Scared, Hostile, Enthusiastic, Proud, Irritable, Alert, Ashamed, Inspired, Nervous, Determined, Attentive, Jittery, Active, and Afraid. A 5-point scale was used where 1 is very slightly or not at all, 2 is a little, 3 is moderately, 4 is quite a bit, and 5 is extremely.

4 weeks
Positive and Negative Affect
Time Frame: 8 weeks

Change in mood is assessed with the PANAS-SF (Positive and Negative Affect Schedule- Short Form).

Participants are asked to evaluate the degree to which they experienced components of positive and negative affect : Interested, Distressed, Excited, Upset, Strong, Guilty, Scared, Hostile, Enthusiastic, Proud, Irritable, Alert, Ashamed, Inspired, Nervous, Determined, Attentive, Jittery, Active, and Afraid. A 5-point scale was used where 1 is very slightly or not at all, 2 is a little, 3 is moderately, 4 is quite a bit, and 5 is extremely.

8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 18, 2024

Primary Completion (Actual)

August 29, 2024

Study Completion (Actual)

October 30, 2024

Study Registration Dates

First Submitted

January 12, 2025

First Submitted That Met QC Criteria

January 30, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 30, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • #STUU524AA0147-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data will need to be protected for patentability reasons while IP is being filed. Once IP considerations are finalized, data can be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atopic Dermatitis (Eczema)

Clinical Trials on Botanical Moisturizer + Unscented Soap

Subscribe